No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

No­vo Nordisk’s $1 bil­lion bet last year on a small Cana­di­an biotech could ex­pand the Dan­ish drug gi­ant’s ar­se­nal of obe­si­ty med­i­cines …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA